English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Meeting Abstract

Development of Ca2+ Responsive Contrast Agents for fMRI

MPS-Authors
/persons/resource/persons84499

Vibhute,  SM
Department Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, Max Planck Society;
Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons84063

Logothetis,  NK
Max Planck Institute for Biological Cybernetics, Max Planck Society;
Department Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, Max Planck Society;

/persons/resource/persons83784

Angelovski,  G
Max Planck Institute for Biological Cybernetics, Max Planck Society;
Department Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, Max Planck Society;

External Resource

Link
(Any fulltext)

Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Vibhute, S., Maier, M., Logothetis, N., & Angelovski, G. (2013). Development of Ca2+ Responsive Contrast Agents for fMRI. In COST TD1004 Action: Theranostics Imaging and Therapy: An Action to Develop Novel Nanosized Systems for Imaging: Guided Drug Delivery (pp. 43).


Cite as: https://hdl.handle.net/21.11116/0000-0001-4EFF-A
Abstract
Magnetic resonance imaging (MRI) using contrast agents has been widely employed in diagnostic imaging and biomedical research. For this purpose, Gd3+ based complexes are commonly utilized. Recently, responsive (smart) contrast agents (SCAs) are being developed in order to aid better understanding of biological processes [1] They are able to report physiological or pathophysiological changes by altering the MR signal they produce.
However the routine in vivo use of SCA is hampered due to challenges such as lack of tools to localize or quantify the agents, low MR signal, non-specific delivery etc. To overcome these challenges, one of the meaningful strategies is to conjugate SCA to various functional molecules such as dendrimers, nanoparticles, delivery vectors or fluorescent tags. The essential requirement when coupling SCAs to functional molecules is retaining their crucial physico-chemical properties in terms of MRI activity.
Hence, the overall objective of our approach was to develop synthetic strategies in which modified DO3A chelator is appended with different linkers for further functionalization. Diverse synthetic strategies were successfully developed using liquid, as well as solid phase chemistry [2]. The SCA were modified and they still robustly response to Ca2+. The newly developed strategies open pathways to improve in vivo applicability of DO3A-based SCAs and to serve as better in vivo reporters in future fMRI experiments.